Results 111 to 120 of about 178,280 (162)
Some of the next articles are maybe not open access.
Ophthalmology Clinics of North America, 2004
Myasthenia gravis may be limited solely to the eyes (ocular myasthenia) or may have systemic manifestations (generalized myasthenia). Most patients display blepharoptosis or ophthalmoparesis, resulting in diplopia, but the ocular motility disorder may take many forms. The diagnosis is often elucidated by variable muscle weakness with fatigability noted
Rachael D, Elrod, David A, Weinberg
openaire +3 more sources
Myasthenia gravis may be limited solely to the eyes (ocular myasthenia) or may have systemic manifestations (generalized myasthenia). Most patients display blepharoptosis or ophthalmoparesis, resulting in diplopia, but the ocular motility disorder may take many forms. The diagnosis is often elucidated by variable muscle weakness with fatigability noted
Rachael D, Elrod, David A, Weinberg
openaire +3 more sources
Current Treatment Options in Neurology, 2005
Myasthenia gravis (MG) is an autoimmune disorder characterized clinically by proximal weakness and bulbar symptoms and pathologically by damage to the post-synaptic membrane at the neuromuscular junction. Ocular myasthenia gravis (ocular MG) is a form of myasthenia gravis whereby the patients' weakness is limited to the muscles of the eyes and eyelids (
Neil C, Porter, Brian C, Salter
openaire +2 more sources
Myasthenia gravis (MG) is an autoimmune disorder characterized clinically by proximal weakness and bulbar symptoms and pathologically by damage to the post-synaptic membrane at the neuromuscular junction. Ocular myasthenia gravis (ocular MG) is a form of myasthenia gravis whereby the patients' weakness is limited to the muscles of the eyes and eyelids (
Neil C, Porter, Brian C, Salter
openaire +2 more sources
Current Treatment Options in Neurology, 2001
Treatment decisions for ocular myasthenia gravis (OMG) should be based on symptomatology. Local, nonpharmacologic treatment of ptosis or diplopia is successful in relatively few patients, and the majority of patients require drug therapy for satisfactory resolution of their symptoms.
Victoria S., Pelak, Steven L., Galetta
openaire +2 more sources
Treatment decisions for ocular myasthenia gravis (OMG) should be based on symptomatology. Local, nonpharmacologic treatment of ptosis or diplopia is successful in relatively few patients, and the majority of patients require drug therapy for satisfactory resolution of their symptoms.
Victoria S., Pelak, Steven L., Galetta
openaire +2 more sources
Current Opinion in Ophthalmology, 2012
To review ocular myasthenia gravis (OMG), a localized form of myasthenia gravis clinically involving only the extraocular, levator palpebrae superioris, and orbicularis oculi muscles.Ocular manifestations can masquerade as a variety of ocular motility disorders, including central nervous system disorders and peripheral cranial nerve palsies.
Michael S, Vaphiades +2 more
openaire +2 more sources
To review ocular myasthenia gravis (OMG), a localized form of myasthenia gravis clinically involving only the extraocular, levator palpebrae superioris, and orbicularis oculi muscles.Ocular manifestations can masquerade as a variety of ocular motility disorders, including central nervous system disorders and peripheral cranial nerve palsies.
Michael S, Vaphiades +2 more
openaire +2 more sources
Russian Annals of Ophthalmology
Myasthenia gravis is an autoimmune disease characterized by muscle weakness and pathological fatigue due to autoaggressive phenomena with the formation of antibodies directed against various structures of the neuromuscular synapse. In most patients, the disease begins with the involvement of extraocular muscles, presenting with symptoms such as ...
M.S. Sergeeva +2 more
openaire +3 more sources
Myasthenia gravis is an autoimmune disease characterized by muscle weakness and pathological fatigue due to autoaggressive phenomena with the formation of antibodies directed against various structures of the neuromuscular synapse. In most patients, the disease begins with the involvement of extraocular muscles, presenting with symptoms such as ...
M.S. Sergeeva +2 more
openaire +3 more sources
Update on Ocular Myasthenia Gravis
Neurologic Clinics, 2017Ocular myasthenia gravis (OMG) is a localized form of myasthenia gravis in which autoantibodies directed against acetylcholine receptors block or destroy these receptors at the postsynaptic neuromuscular junction. The hallmark of OMG is a history of painless weakness or fatigability of the extraocular muscles and ptosis with normal pupillary function ...
Stacy V, Smith, Andrew G, Lee
openaire +2 more sources
Ocular Aspects of Myasthenia Gravis
Seminars in Neurology, 2000Ocular myasthenia gravis is a not uncommon autoimmune disorder causing diplopia, ptosis, and weakness of lid closure. The predilection of myasthenia for the ocular muscles may be related to differences between limb and extraocular muscles in either physiological function or antigenicity. Clinically, ocular myasthenia can mimic any form of pupil-sparing
J J, Barton, M, Fouladvand
openaire +2 more sources
Update on Ocular Myasthenia Gravis
Seminars in Neurology, 2019AbstractMyasthenia gravis is an antibody-mediated autoimmune disorder of the post-synaptic neuromuscular junction resulting in fluctuating, fatigable weakness. Most patients first present with extraocular symptoms (diplopia and/or ptosis), and in 15% of cases symptoms will remain restricted to only the extraocular muscles (ocular myasthenia gravis [OMG]
Meabh, O'Hare, Christopher, Doughty
openaire +2 more sources
Childhood ocular myasthenia gravis
Ophthalmology, 2003To investigate the clinical manifestations and ocular findings in children with ocular myasthenia gravis (MG) that rarely have been reported in the literature.Retrospective, noncomparative case series.Twenty-four consecutive patients less than 15 years of age with ocular MG treated between June 1988 and July 2001.The medical records of 6 boys and 18 ...
Jong-Hyun, Kim +4 more
openaire +2 more sources
Treatment of Ocular Myasthenia Gravis
Current Treatment Options in Neurology, 2011Myasthenia gravis (MG) is an autoimmune disorder that is characterized by variable weakness and fatigability. Often, MG presents with only ocular symptoms such as ptosis and diplopia. Treatment of ocular MG is aimed at relieving the symptoms of ptosis and diplopia, as well as preventing the development of generalized MG symptoms.
Scott R, Haines, Matthew J, Thurtell
openaire +2 more sources